volume 2, issue 8, PS411-S412 2007
DOI: 10.1097/01.jto.0000283296.10960.ac
View full text
|
|
Share

Abstract: Background: In advanced NSCLC, E and B either as a single agent (E) or in combination with chemotherapy (B) have shown to improve survival. Combinations of targeted agents may prove to be effective and better tolerated than chemotherapy. Methods: This is a multicenter 2-stage phase II study (Simon's optimal design; p0=40%, p1=60%, α=0.05, β=0.20) with early stopping rule .The primary endpoint is non-progression (NPR) at 6 weeks. When 24/46 pts have NPR at 6 wks the treatment will be declared to have sufficient…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals